New strengths of Targinact

Napp has launched two new strengths of Targinact (oxycodone/naloxone). The 5mg/2.5mg and 40mg/20mg tablets provide greater dosing flexibility.

The starting dose remains 10mg/5mg, but the new lower-strength tablet allows a more gradual and individually tailored approach to dose titration. The new higher-strength preparation reduces tablet burden for patients requiring the maximum dose.

Furthermore, Targinact is now licensed for use at doses up to a maximum of 80mg oxycodone hydrochloride/40mg naloxone hydrochloride daily.

View Targinact drug record

Further information: Napp

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Added: azathioprine.
Use our constantly updated...

New MIMS section offers external resources to benefit your practice

New MIMS section offers external resources to benefit your practice

MIMS Hosted is a new section of the MIMS website providing...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

New headache toolkit offers tips to improve management in primary care

New headache toolkit offers tips to improve management in primary care

GPs should use standardised headache assessment criteria...